Elan to lay off 230 in retooling

Embattled Irish drugmaker Elan plans to cut 230 positions, or 14 percent of its work force, as it postpones biologics manufacturing and realigns the R&D operations within its biopharmaceutical business. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.